Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer

  • Dennis J. Slamon
    Division of Hematology-Oncology, Department of Medicine, and the Jonsson Comprehensive Cancer Center, U.C.L.A. School of Medicine, Los Angeles, CA 90024.
  • William Godolphin
    Department of Clinical Chemistry, Vancouver General Hospital, Vancouver, Canada VSZIM9.
  • Lovell A. Jones
    Department of Gynecology, M. D. Anderson Hospital, Houston, TX 77030.
  • John A. Holt
    Department of Obstetrics and Gynecology, University of Chicago Medical Center, Chicago, IL 60637.
  • Steven G. Wong
    Division of Hematology-Oncology, Department of Medicine, and the Jonsson Comprehensive Cancer Center, U.C.L.A. School of Medicine, Los Angeles, CA 90024.
  • Duane E. Keith
    Division of Hematology-Oncology, Department of Medicine, and the Jonsson Comprehensive Cancer Center, U.C.L.A. School of Medicine, Los Angeles, CA 90024.
  • Wendy J. Levin
    Division of Hematology-Oncology, Department of Medicine, and the Jonsson Comprehensive Cancer Center, U.C.L.A. School of Medicine, Los Angeles, CA 90024.
  • Susan G. Stuart
    Triton Biosciences, Inc., Alameda, CA 94501.
  • Judy Udove
    Department of Pathology, University of Southern California, School of Medicine, Los Angeles, CA 90033
  • Axel Ullrich
    Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 94080.
  • Michael F. Press
    Department of Pathology, University of Southern California, School of Medicine, Los Angeles, CA 90033

抄録

<jats:p> Carcinoma of the breast and ovary account for one-third of all cancers occurring in women and together are responsible for approximately one-quarter of cancer-related deaths in females. The HER-2/ <jats:italic>neu</jats:italic> proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior. In this report, several similarities were found in the biology of HER-2/ <jats:italic>neu</jats:italic> in breast and ovarian cancer, including a similar incidence of amplification, a direct correlation between amplification and over-expression, evidence of tumors in which overexpression occurs without amplification, and the association between gene alteration and clinical outcome. A comprehensive study of the gene and its products (RNA and protein) was simultaneously performed on a large number of both tumor types. This analysis identified several potential shortcomings of the various methods used to evaluate HER-2/ <jats:italic>neu</jats:italic> in these diseases (Southern, Northern, and Western blots, and immunohistochemistry) and provided information regarding considerations that should be addressed when studying a gene or gene product in human tissue. The data presented further support the concept that the HER-2/ <jats:italic>neu</jats:italic> gene may be involved in the pathogenesis of some human cancers. </jats:p>

収録刊行物

  • Science

    Science 244 (4905), 707-712, 1989-05-12

    American Association for the Advancement of Science (AAAS)

被引用文献 (150)*注記

もっと見る

キーワード

詳細情報

問題の指摘

ページトップへ